The psychedelic therapy society Sunstone Therapies recently announced the launch of its first study on the use of multiple doses of psilocybin In the treatment of major depressive disorder (TDM) in cancer patients.
This phase 2 study, which takes place at the Bill Richards Center for Healing of the Aquilino Cancer Center, aims to assess the safety and efficiency of psilocybin in a therapeutic context.
The need for effective treatment for emotional distress in cancer patients
The emotional distress associated with cancer can be as overwhelming as the physical effects of the disease. Unfortunately, oncologists have little effective treatments to approach this crucial aspect of the patient's experience. This is why the use of therapy assisted by psychedelics has aroused renewed interest in recent years. Many studies have shown a positive impact of these therapies on symptoms of depression in cancer patients.
Study objectives:
The study by Sunstone Therapies aims to deepen knowledge on the use of psilocybin in the treatment of CT in patients with cancer. This two -part study will include up to 56 participants and will examine the effectiveness of two doses of 25 mg of psilocybin administered at an interval of 9 to 10 weeks.
Part 1: Double blind, randomized and controlled by placebo study
The first part of the study will consist of administering a first dose of psilocybin in a double blind, randomized and controlled by placebo setting. This will evaluate the effect of psilocybin in relation to a placebo and to determine its potential effectiveness in the treatment of CT in patients with cancer.
Part 2: Open study for non-repayers
The second part of the study will take the form of an open study for patients who do not reach the remission of depression symptoms after the first dose of psilocybin. These patients will have the opportunity to receive a second dose of 25 mg of psilocybin in a group framework.
Therapeutic supervision and support
All participants in the study will be accompanied by a study therapist during the first dosage sessions. In addition, a second therapist will monitor the sessions remotely via a video stream. This approach guarantees that participants benefit from therapeutic support throughout the study.
Unique contributions from Sunstone Therapies
Sunstone Therapies is a company engaged in clinical research on psychedelic assisted therapy in cancer patients. Their experience in psychedelic methods allows them to design innovative clinical trials. This new study on the use of multiple doses of psilocybin marks an important advance in understanding the effectiveness of this therapy and the best way to administer it.
Effectiveness evaluation criteria
The evaluation of the effectiveness of the study will be based on several criteria, in particular the modification of the scale of evaluation of the depression of Montgomery-Asberg (MADRS) between the start of the study and the week 8. D D 'Other secondary criteria will include the appearance and sustainability of the response, the rate of response and remission, as well as the effect of psilocybin on pain.
Video on patient treatment in depression, Radio Canada Montreal:
Magic mushrooms are used for patients refracted to conventional treatments for depression, note that the psilocybine is supervised by doctors, psychotherapists:
Conclusion
The study by Sunstone Therapies on the use of multiple doses of psilocybin in the treatment of depression in cancer patients constitutes a promising advance in the field of therapy assisted by psychedelics. This research could help improve the quality of life of patients and to define the best practices for the use of this potentially vital treatment modality.
To read: Jimmy Mohamed: Psilocybine microdosage for depression?
Faq
Q1: What is psilocybin?
A1: Psilocybin is a psychoactive compound present in hallucinogenic mushrooms, also known as magic mushrooms.
Q2: What is therapy assisted by psychedelics?
R2: Therapy assisted by psychedelics is a therapeutic approach that uses psychedelic substances under the supervision of a therapist to promote deep introspection and psychedelic experiences.
Q3: What is major depressive disorder (CTC)?
A3: Major depressive disorder is a serious form of depression characterized by a persistent depressive mood, a loss of interest in activities and physical symptoms such as sleep and appetite disorders.
Q4: What are the other potential applications of psilocybin?
R4: In addition to the treatment of depression in cancer patients, psilocybin is also studied for its potential in the treatment of disorders such as anxiety, post-traumatic stress disorder (TTEP) and dependence.
Q5: What are the potential side effects of psilocybin?
R5: The side effects of psilocybin may include hallucinations, disturbances in perception and mood changes. However, when used in an appropriate therapeutic framework and supervised by health professionals, psilocybin is generally considered safe.
Q6: What is the importance of this study for cancer patients?
R6: This study could open up new treatment prospects for cancer patients by providing an effective therapeutic option for emotional distress associated with the disease.
Q7: When will the results of this study available?
R7: The results of the study will be available once all the data has been analyzed and interpreted. It is important to conduct rigorous research to guarantee reliable and significant results.
Q8: How will the study participants be selected?
R8: Study participants will be selected according to specific criteria defined by researchers, such as the diagnosis of cancer and the presence of depressive symptoms. Participants must also meet certain health and safety conditions.
Q9: What are the recent progress in the field of therapy assisted by psychedelic?
R9: In recent years, research on the therapy assisted by psychedelics has experienced significant growth, with many studies demonstrating its potential efficiency in the treatment of various mental and emotional disorders.
Q10: What are the prospects for the future of therapy assisted by psychedelics?
R10: As research continues to progress, it is possible that therapy assisted by psychedelics will become a more widely accepted treatment method used in the field of mental health. However, additional research and rigorous clinical trials are necessary to fully assess its effectiveness and safety.
